TP53 and cancer: Among the patients with LFS with variant TP53, the WNT β-catenin signaling pathway was significantly mutated in the germline of 23% (3/13) of individuals who were cancer-free compared with 2% (1/49) of patients that developed cancer (Wilcoxon rank-sum test, FDR = 0.08).